Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series-Reference-Cited by-同舟云学术

Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series

Published:2022-08-09 Issue: Volume:9 Page:
ISSN:2297-055X
Container-title:Frontiers in Cardiovascular Medicine
language:
Short-container-title:Front. Cardiovasc. Med.

Author:

Chye Adrian M.,Nordman Ina I. C.,Sverdlov Aaron L.

Abstract

Pericardial diseases secondary to immune checkpoint inhibitors (ICI) are rare. Here, we describe two cases of immune-related pericarditis caused by ICI for treatment of advanced NSCLC. Select patients can be successfully rechallenged with ICI after immune-related pericardial disease.

Funder

National Heart Foundation of Australia

Publisher

Frontiers Media SA

Subject

Cardiology and Cardiovascular Medicine

Reference11 articles.

1. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer;Reck;New Engl J Med.,2016

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet.,2016

3. Clinical features, management, and outcomes of immune checkpoint inhibitor–related cardiotoxicity;Escudier;Circulation.,2017

4. Pericardial effusion due to pembrolizumab-induced immunotoxicity: A case report and literature review;Atallah-Yunes;Curr Probl Cancer,2019

5. Cardiac tamponade and adrenal insufficiency due to pembrolizumab: a case report;Oristrell;Eur Heart J Case Rep,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms, Clinical Management and Innovative Treatment;Drug Design, Development and Therapy;2024-09

2. The broad spectrum of cardiotoxicities from immunotherapies;Frontiers in Cardiovascular Medicine;2023-09-15

3. Nivolumab/pembrolizumab/vinorelbine;Reactions Weekly;2022-10-08